Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.65 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512175 | 0.86 | SRD5A2 (0.61) | SMN1; SMN2SRD5A2PLA2G4BPKMPLA2G4A | |
| SCHEMBL334299 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2SRD5A2KEAP1NFE2L2TP53 | |
| SCHEMBL25214495 | 0.85 | KEAP1 (0.76) | KEAP1NFE2L2 | |
| SCHEMBL25201603 | 0.85 | KEAP1 (0.76) | KEAP1NFE2L2 | |
| SCHEMBL3632818 | 0.83 | SMN1; SMN2 (0.86) | SMN1; SMN2KEAP1NFE2L2MAPK1 | |
| SCHEMBL6539987 | 0.83 | SRD5A2 (0.91) | SRD5A2PLA2G4BPKMPLA2G4AMAPK1 | |
| SCHEMBL186922 | 0.83 | MAPT (0.64) | SMN1; SMN2KEAP1NFE2L2MAPK1TP53 | |
| SCHEMBL14220752 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2TP53 | |
| SCHEMBL1958617 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KEAP1NFE2L2MAPK1TP53 | |
| SCHEMBL27722433 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2KEAP1NFE2L2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | SMN1; SMN2 2439/4885SRD5A2 507/4885PLA2G4B 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.